TYRA
What one share of Tyra Biosciences holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology.
Tyra Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.40 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.78 |
| Cash and investments | $1.24 |
| Book value | $5.93 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$6.05 | $0.20 | −$5.24 | — | −$7.46 |
| 2021 | — | −$1.91 | $0.05 | −$1.77 | — | — |
| 2022 | — | −$1.32 | $0.01 | −$1.21 | — | $6.09 |
| 2023 | — | −$1.62 | $0.02 | −$1.19 | — | $4.75 |
| 2024 | — | −$1.51 | $0.01 | −$1.23 | — | $6.76 |
| 2025 | — | −$2.01 | $0.00 | −$1.60 | — | $4.83 |